Gennova malaria vaccine

Gennova Biopharmaceuticals is developing a malaria vaccine candidate that is currently in the preclinical stage. The vaccine is designed to induce protective immune responses against *Plasmodium* antigens to prevent malaria infection. The development program has involved collaborations with international organizations such as the PATH Malaria Vaccine Initiative (MVI). Gennova utilizes its expertise in recombinant DNA technology and various expression systems—including bacterial, mammalian, and yeast-based platforms (notably *Pichia pastoris*)—to produce the vaccine antigens. While the specific antigenic targets for this candidate are not publicly detailed in the current pipeline, the company has a history of working on recombinant proteins for endemic diseases, including transmission-blocking targets like Pfs25.

Other names

malaria vaccine (Gennova)Genova malaria vaccine